Table 4. All adverse events for patients receiving continuous temozolomide (cTMZ) dosing and iniparib.
| Adverse Event | Grade 1 No. (% of pts) |
Grade 2 No. (% of pts) |
Grade 3 No. (% of pts) |
Grade 4 | Total No. (% of pts) |
|---|---|---|---|---|---|
| ALT | 6 (30) | 6(30) | |||
| Alkaline phosphatase | 1 (5) | 1 (5) | |||
| Anemia | 9 (45) | 1 (5) | 1 (5) | 11 (55) | |
| Anorexia | 2 (10) | 1 (5) | 3 (15) | ||
| AST | 2 (10) | 2 (10) | |||
| Blurred vision | 1 (5) | 1 (5) | |||
| Constipation | 5 (25) | 2 (10) | 7 (35) | ||
| Elevated serum creatinine | 1 (5) | 1 (5) | |||
| Cushingoid | 1 (5) | 1 (5) | |||
| Dehydration | 1 (5) | 1 (5) | |||
| Diarrhea | 1 (5) | 1 (5) | |||
| Dry skin | 1 (5) | 1 (5) | |||
| Dysgeusia | 1 (5) | 1 (5) | |||
| Edema limbs | 1 (5) | 1 (5) | |||
| Erythema multiforme | 1 (5) | 1 (5) | |||
| Fatigue | 6 (30) | 9 (45) | 15 (75) | ||
| Flatulence | 1 (5) | 1 (5) | |||
| Flushing | 2 (10) | 2 (10) | |||
| GI complaints | 1 (5) | 1 (5) | |||
| Hypoalbuminemia | 1 (5) | 1 (5) | |||
| Injection site reaction | 1 (5) | 1 (5) | |||
| Insomnia | 3 (15) | 3 (15) | |||
| Intracranial haemorrhage | 1 (5) | 1 (5) | |||
| motion decreased | 1 (5) | 1 (5) | |||
| Mucositis oral | 1 (5) | 1 (5) | |||
| Nausea | 7 (35) | 1 (5) | 1 (5) | 9 (45) | |
| Nervous system | 1 (5) | 1 (5) | |||
| Pain | 1 (5) | 1 (5) | |||
| Pruritus | 1 (5) | 2 (10) | 3 (15) | ||
| Rash maculo-papular | 1 (5) | 1 (5) | 2 (10) | ||
| Urinary frequency | 1 (5) | 1 (5) | |||
| Vomiting | 2 (10) | 2 (10) | |||
| Weight loss | 1 (5) | 1 (5) | |||
| Thromboembolic event | 1 (5) | 1 (5) | |||
| Platelet decreased | 5 (25) | 1 (5) | 6 (30) | ||
| White blood cell decreased | 7 (35) | 7 (35) | 4 (20) | 1 (5) | 19 (95) |
(Bold indicates met criteria for DLT)